The causes of bradycardia in athletes
The effects of ivabradine under autonomic blockade in endurance athletes.
Baker Heart and Diabetes Institute
30 participants
Jul 18, 2017
Interventional
Conditions
Summary
It is well known that athletes have lower heart rates (bradycardia) than non-athletes. This is generally considered a healthy adaptation. However, bradycardia has been associated with the subsequent development of atrial fibrillation (AF), an arrhythmia known to increase the risk of heart failure, stroke and even death. Consequently, bradycardia could conceivably be associated with significant problems later in life. The reasons athletes have slow heart rates are not well understood. Traditionally changes in neural input (vagal tone) were thought to lead to bradycardia in athletes. However, several studies have demonstrated that even after blocking these inputs(autonomic blockade), athletes continue to have lower heart rates than non-athletes. The reasons for this are not known however recent research using athlete mice models suggests this is due to intrinsic changes within the heart by downregulation of the HCN4 gene. In the mouse model, the medication which blocks this gene, ivabradine, helped to equalize the heart rates in athlete and non-athlete mice. Our aim in this study is to understand the reason for lower heart rates in endurance athletes. Participants will undergo repeat testing under experimental conditions to help determine the causes of low heart rates in athletes. We hypothesize that ivabradine will be less effective in athletes, ie it will lower the heart rate of athletes less than nonathletes. This would suggest that bradycardia in athletes is associated with changes within the heart rather than reversible changes in neural inputs. This may provide some insights into the mechanism of atrial fibrillation in athletes.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervention: Autonomic blockade with single doses of intravenous metoprolol(0.2mg/kg) + intravenous atropine (0.04mg/kg) plus oral ivabradine 15mg Exposure: endurance sport participation A wash out period of at least 24 hours will occur before crossover to the control arm
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617000983303